Drug Profile
AB 3001
Alternative Names: AB-3001Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Abeille Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic syndrome
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Metabolic-syndrome in USA (PO, Controlled release)
- 26 Apr 2017 Preclinical trials in Metabolic syndrome in USA (PO)